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ABSTRACT
Purpose: The expression and involvement of estrogen (ER) and progesterone 
receptor (PR) is extensively studied in endometrial cancer. Androgen receptor (AR) 
is a hormone receptor less studied in female cancers, and we here aim to investigate 
the expression level of AR in endometrial cancer precursor lesions, primary tumors 
and metastases, and its potential as therapeutic target. 
Results: Expression of AR was observed in 93% of hyperplasias, but only in 41% 
of non-endometrioid tumors. Compared to estrogen and progesterone receptor AR 
is more commonly expressed in metastatic lesions, and AR status is discordant in 
primary and metastatic lesions in a large proportion of cases. AR protein level was 
significantly associated with survival (P < 0.001), and a calculated AR to ERα ratio 
identified a subgroup of patients with particular poor outcome. The anti-androgen 
enzalutamide may have a growth inhibitory effect in endometrial cancer cells based 
on experiments with primary endometrial tumor cells.
Materials and Methods: 718 primary endometrial cancers and 298 metastatic 
lesions (from 142 patients) were investigated for expression of AR in relation to 
survival, clinical and histopathological data. Protein levels were investigated by 
immunohistochemistry and reverse phase protein array; mRNA levels by DNA 
oligonucleotide microarray. The effect of androgen stimulation and inhibition was 
tested on primary endometrial tumor cells.
Conclusions: A large proportion of metastatic endometrial cancer lesions express 
AR, which may be a potential target in these patients. Treatment targeting AR may 
be of particular benefit in patients with high AR levels compared to ERα levels.
INTRODUCTION 
Endometrial cancer is the most common 
gynecological malignancy in the Western countries [1]. 
Little progress has been made in development of treatment 
options over the past decades. This, combined with a rising 
incidence, has resulted in an increased number of deaths 
caused by the disease [2]. Although patients with localized 
disease have a good prognosis, prognosis is poor for 
patients with recurrence or metastatic disease at diagnosis 
and treatment options are few [3]. To improve treatment of 
this patient group, both the identification of new treatment 
targets, and identification of potent biomarkers to aid 
patient stratification are vital.
Traditionally, endometrial cancers have been divided 
into two groups. Type I, accounting for approximately 
               Research Paper
Oncotarget49290www.impactjournals.com/oncotarget
80% of cases, is associated with endometrioid histology, 
low stage and grade, good prognosis and estrogen 
dependency [3, 4]. Type II tumors are associated with non-
endometrioid histology, high stage and grade and poor 
prognosis [3]. The majority of endometrial cancers are 
hormone dependent, and hormonal dysregulation is linked 
to disease development and progression [5]. The role and 
expression of estrogen and progesterone receptors (ERα 
and PR) in endometrial cancer have been extensively 
studied [5]. ERα and/or PR positivity in primary tumors 
is associated with well-differentiated lesions and more 
favorable prognosis [6, 7]. Hormonal therapy targeting 
both PR and ERα is used in treatment of endometrial 
cancer. The response rate to such treatments is usually low 
[8], however, patients expressing hormone receptors have 
been shown to be more sensitive to hormonal therapy [2]. 
Androgen receptor (AR) is a hormone receptor 
less studied in endometrial cancer, although a target for 
treatment in other cancers [9, 10]. It is expressed in several 
tissues, including the uterus, where its role is largely 
unknown [10, 11]. In males, aberrant androgen signaling 
is central to initiation and progression of prostate cancer 
[12, 13]. Treatment targeting AR or androgen synthesis is 
therefore one of the main therapeutic elements in patients 
with hormone dependent prostate cancer [9]. Recently, also 
in breast cancer treatment, targeting AR has been suggested 
beneficiary for specific subgroups of patients [10].
Given the similarities of breast and endometrial 
cancers, exploring AR expression in endometrial cancer 
might reveal new therapeutic strategies. Additionally, AR 
status in malignant endometrial lesions may be related to 
clinical phenotype and could represent a novel biomarker 
for prognosis.
RESULTS
AR is expressed in the majority of hyperplasias 
and primary endometrial cancer lesions
The expression pattern of AR was investigated 
in relation to aggressiveness of endometrial cancer. AR 
staining was predominantly nuclear, and only staining 
in glandular tissue was scored (Figure 1A and 1B). 
Precursor lesions were included to investigate if there 
was a change in expression from the pre-malignant to the 
malignant stage. Hyperplasias had the highest level of AR 
expression. Of the 69 hyperplasias evaluated, 93% (64 
patients) expressed AR. In primary tumors the percentage 
of lesions with AR expression decreased significantly from 
74% to 53% from endometrioid grade 1 to grade 3 tumors 
respectively and further to 41% in non-endometrioid 
tumors (Figure 1C). This pattern was reflected when 
assessing mRNA levels (Figure ID), and there was 
significant overlap between AR expression evaluated by 
IHC and AR mRNA expression (Supplementary Figure 1). 
AR is frequently expressed in metastatic lesions 
of endometrial cancer
As for most cancers, metastatic endometrial 
cancers have high mortality and few treatment options. 
Characterization of metastatic lesions is therefore highly 
important, especially considering molecular targets with 
existing therapeutics. Expression was investigated in 
298 metastatic lesions from 142 patients (Supplementary 
Table 1). We observed that a high number of the metastatic 
lesions express AR. For patients with corresponding 
metastatic lesions AR, PR and ERα was expressed in 
48%, 61% and 52 % of the primary tumors respectively 
(Figure 2A, 2D and 2G). In metastases from hormone 
receptor (AR, PR or ERα) positive primary tumors, 
expression was retained in at least one metastatic lesion 
in 71% of cases for AR, 58% for PR and 64% for ERα 
(Figure 2B, 2E and 2H). Also 44% of patients defined to 
have lost expression of AR in the primary tumor expressed 
AR in at least one metastatic lesion (Figure 2C). For ERα 
and PR this was only 20% (Figure 2F and 2I). AR, PR 
and ERα were investigated in individual metastases 
to compare expression patterns. A high degree of 
heterogeneity in hormone receptor expression was 
observed both in metastases from AR positive primary 
tumors (Figure 2J) and AR negative primary tumors 
(Figure 2K). 39% of the metastatic lesions expressing AR 
had low expression of ERα.
Expression of AR is associated with good 
survival
Loss of AR was significantly associated with 
established features of aggressive tumors, such as high 
FIGO stage (P < 0.001), non-endometrioid histology 
(P < 0.001) and high grade within the endometrioid 
subgroup (P = 0.001) (Table 1). The relation between 
disease specific survival and AR expression was 
investigated using groups with high and low expression 
of AR as defined in the method section. AR loss associated 
with shorter disease specific survival both in the whole 
population (Figure 3A) and within the subgroup of 
patients with disease confined to the uterus, FIGO stages 
I/II (Figure 3B). In multivariate survival analyses AR did 
not demonstrate independent prognostic impact when 
adjusting for factors with known prognostic value (age, 
histologic type and grade) (p = 0.12, data not shown), 
indicating that loss of AR may not add additional 
information regarding survival when used in a clinical 
setting. Still, the high number of primary tumors and 
metastatic lesions with intact expression of AR could 
point to an unexploited potential for treatment targeting 
AR in endometrial cancer, and it might be of particular 
interest in specific subgroups as observed for other cancer 
types.
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High AR to ERα ratio identifies patients with 
particularly poor survival
Based on previous findings in breast cancer, we 
hypothesized that also for endometrial cancer, the effect of 
AR signaling may be influenced by the presence of ERα. 
Interestingly, the patients with the highest calculated AR 
to ERα ratio (based on RPPA data) had significantly worse 
survival, both in the whole population (Figure 4A) and 
in FIGO stages I/II (Supplementary Figure 2A). A high 
ratio was also significantly associated with established 
features of aggressive tumors (Supplementary Table 2). 
In a subpopulation with especially long follow up, a high 
AR to ERα ratio, calculated based on mRNA levels, also 
identified a patient group with significantly worse survival 
compared with patients with a low AR to ERα ratio, both 
in the whole population (Supplementary Figure 2B) and in 
FIGO stages I/II (Supplementary Figure 2C). 
The underlying mechanisms involved were explored 
by investigating transcriptional alterations related to the 
high AR to ERα ratio group. In GSEA analysis several of 
the top ranked GO gene sets enriched in the high AR to 
ERα ratio group were associated with cell cycle regulation 
(Supplementary Table 3). This finding was supported by 
the significantly higher proliferation identified in patients 
with high AR to ERα ratio, assessed both by high cell 
cycle progression (CCP) score and high proliferation cell 
nuclear antigen (PCNA) levels (measured by Reverse 
Phase Protein Array) (Figure 4B and 4C). 
To explore if transcriptional alterations related 
to the high AR to ERα ratio could suggest new targets 
for treatment, Connectivity map was queried for drug 
signatures negatively correlated with the gene expression 
profile of tumors with a high AR to ERα ratio. Compounds 
targeting phosphoinositide 3-kinase (PI3K)/mammalian 
target of rapamycin (mTOR) pathway were among the top 
ranked, along with HSP90 inhibitors, known to disrupt 
hormone binding and hormone receptor stability [14], 
the AR inhibitor Resveratol [15, 16] and a CDK inhibitor 
[17] (Supplementary Table 4). These findings suggest that 
drugs targeting proliferation and anti-androgen treatment 
could be potential treatment options for the high AR to 
ERα ratio patient subgroup in particular. Supporting this, 
preliminary results in short-term cultures of AR positive 
(defined by IHC staining of patient biopsy) primary 
endometrial tumor cells, proliferation was significantly 
inhibited by the anti-androgen enzalutamide, and there was 
a tendency to increased proliferation after stimulation with 
the synthetic androgen R1881, although not statistically 
significant. No effect was seen in AR negative or focal 
positive cells (data not shown). 
DISCUSSION
Several studies have demonstrated that ERα and PR 
status are important prognostic biomarkers, also predicting 
response to anti-hormonal therapy in endometrial cancer 
[6, 7]. For AR available data is more limited.  It is still 
unsettled if AR could predict outcome and also, whether 
there is a role for androgen targeting drugs in endometrial 
cancer treatment. The published studies are few with 
low number of included patients, leaving inconclusive 
results [18–24]. In the present study, to date the largest 
and most comprehensive study with extensive clinical 
annotation and samples ranging from precursors through 
primary to metastatic endometrial carcinoma lesions, we 
find that precursor lesions and well-differentiated primary 
tumors have the highest level of AR, with a gradual 
Figure 1: AR expression decreases with dedifferentiation. AR expression in glandular cells was scored, with strong AR 
immunohistochemical staining shown in (A) and AR loss in (B). Both AR protein level (C) and mRNA (D) level decreased with 
dedifferentiation. Abbreviations: AR: androgen receptor, Gr: grade, NE: non-endometrioid, PT: primary tumor, Met: metastases, 
*Information on grade missing for 10 patients included in the study (7 AR positive and 3 AR negative)
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decrease in AR level with dedifferentiation. This pattern 
is consistently found using different methods to assess AR 
levels. Our findings thus appear to be in line with previous 
smaller studies, reporting AR loss ranging from 11.4% 
in endometrioid primary tumors [25] to 79% in a study 
including primary tumors of different histological subtypes 
[26]. A significant association between dedifferentiation 
and AR loss has also been reported in a small study 
including 35 patients [27]. In this study we show that also 
AR is a prognostic marker in endometrial cancer as earlier 
well documented for ERα and PR [6, 28–30].
The extensive experience with anti-androgen 
treatment in prostate cancer makes it attractive for 
investigation also in other hormone dependent cancers. 
There are several available anti-androgen treatments 
with different mechanism of action. The anti-androgen 
bicalutamide inhibits binding of ligand to the androgen 
receptor, while enzalutamide, a second generation 
anti-androgen, inhibits several steps of AR activation. 
Inhibition of AR signaling can also be achieved through 
inhibition of ligand synthesis. Abiraterone inhibits 
the enzyme CYP17 which is necessary for androgen 
biosynthesis [31].  Although our findings show that AR 
expression is associated with low grade tumors, it may, 
analogous to ERα, still be a driver for tumor growth and 
therefore a potential therapeutic target. Our preliminary 
Table 1: Clinico-pathological variables related to androgen receptor (AR) status in endometrial 
cancer patients
AR
Variable Positive n (%) Loss n (%) P-value
Age 0.7
   < 66 229 (63) 135 (37)
   ≥ 66 218 (62) 136 (38)
FIGO-09 stage < 0.001
   I–II 396 (66) 204 (34)
   III–IV 51 (43) 67 (57)
Histologic type < 0.001
   Endometrioid 386 (67) 188 (33)
   Adenosquamous 4 (67) 2 (33)
   Clear cell 7 (25) 21 (75)
   Serous papillary 36 (55) 29 (45)
   Carcinosarcoma 13 (41) 19 (59)
   Undifferentiated/other 1 (7) 12 (92)
Histologic grade* 0.001
   Grade 1/2 329 (70) 140 (30)
   Grade 3 50 (53) 45 (47)
Metastatic nodes < 0.001
   Negative 333 (65) 176 (35)
   Positive 28 (42) 39 (58)
Ploidy 0.3
   Diploid 223 (64) 128 (36)
   Aneuploid 59 (58) 43 (42)
PR < 0.001
   Positive 391 (74) 137 (26)
   Negative 40 (26) 115 (74)
ERa < 0.001
   Positive 390 (78) 113 (22)
   Negative 42 (23) 140 (77)
*only endometrioid, missing information on grade for ten cases.
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Figure 2: Expression of the individual hormone receptors AR, PR and ERα in metastatic lesions based on its expression 
in primary tumor. 48% of the primary tumors with corresponding metastatic lesions were AR positive (IHC score 1–9) (A). Graphs 
show distribution of AR expression in the metastatic lesions from AR positive primary tumors (B) and AR negative primary tumors (C). 
61% of the primary tumors with corresponding metastatic lesions were PR positive (IHC score 1–9) (D). Graphs show distribution of PR 
expression in the metastatic lesions from the PR positive primary tumors (E) and PR negative primary tumors (F). 52% of the primary 
tumors with corresponding metastatic lesions were ER positive (IHC score 4–9) (G). Graphs show distribution of ER expression in the ER 
positive primary tumors (H) and ER negative primary tumors (I). Expression patterns in individual metastases from AR positive patients 
(J) and AR negative patients (K) are shown as AR (purple), PR (green) and ERα (orange) in J and K. One line of circles represents one 
metastasis, and shows the difference in hormone receptor expression in that specific metastasis. Only patients with one or more AR positive 
metastases are shown. *Only primary tumors with corresponding metastases included.
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Figure 3: AR status predicts prognosis in endometrial cancer. Endometrial cancer patients with AR expression (scoring index 
1–9) have a significantly better survival than patient with AR loss (scoring index 0) both in the whole population (A) and in the subgroup 
of patients with FIGO stage I and II (B).
Figure 4: High AR to ER ratio identifies a subgroup with particularly poor survival. Patients with a high AR to ERα ratio 
assessed by Reverse Phase Protein Array demonstrate a particularly poor disease specific survival compared to patients with a low AR to 
ERα ratio (A). The group with high AR to ERα ratio had significantly higher CCP score (B) and PCNA expression (C) compared to the 
group with low AR to ERα ratio.
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results indicate that enzalutamide may inhibit proliferation 
in AR positive primary endometrial cancer cells. This is an 
interesting observation that calls for follow-up functional 
studies. There are few studies investigating the effect of 
AR signaling on endometrial cells, and the results from 
these studies are contradictory. Different mechanisms have 
been suggested by which androgens may exert their effect 
on the endometrium. The proliferative effects of androgen 
have been linked to enhancement of EGF action [18], 
increased expression of genes involved in IGF-1 and Wnt 
signaling [19] or to endometrial cancer cell proliferation 
through activation of the oncogene c-myc [20]. These 
studies are however contradicted by the finding that 
androgens inhibit proliferation of endometrial cells in vitro 
[21, 22], and several studies on the weakly AR positive 
endometrial cancer cell line MFE-296 demonstrating 
growth inhibition by androgen stimulation [23, 24]. These 
conflicting results could imply different roles for AR at 
different stages of endometrial cancer and indicate that 
AR signaling is context-dependent. This is in line with 
our finding that a subgroup of patients with high AR to 
ERα ratio has particularly poor survival, indicating that 
ERα status may influence the effect of AR. Our findings 
are also in line with previous observations from breast 
cancer, where the prognostic value of AR is improved by 
combining AR and ERα status [32, 33]. Cochrane et. al. 
found that a high AR to ERα ratio was an independent 
predictor of disease-free and disease specific survival in 
breast cancer [34]. Studies are ongoing in breast cancer 
to investigate the effect of anti-androgen treatment 
in patients with AR positive tumors with loss of ERα 
and PR (ClinicalTrials.gov Identifier NCT00468715, 
NCT01889238). Similar studies in endometrial cancer 
patients could reveal whether AR could be a potential 
target also in endometrial cancer patients with high AR 
to ERα ratio.
Hormonal treatment targeting ERα and PR is found 
to be most effective if the hormone receptor is expressed 
[2, 35]. Since the expression of these hormone receptors is 
discordant between primary and metastatic lesions [6, 36], 
investigating the expression status also in the metastatic 
setting is important. We find that AR is more often expressed 
in metastatic lesions compared to ER and PR, but also AR 
expression is discordant in primary and metastatic lesions 
in a large proportion of cases. Since a large proportion of 
metastatic endometrial cancers express AR, this may serve 
as a potential therapeutic target for this patient group, and 
particularly in the group with a high AR to ERα ratio. 
As there are several available treatments targeting AR, 
further studies should be conducted to investigate their 
potential in treatment of endometrial cancer. This study 
also underlines the need to examine metastatic expression 
of potential therapeutic targets, as multiple studies have also 
done concerning other biomarkers and targets [6, 36–38], 
and clearly demonstrates that the primary tumor is not 
representative for its metastatic lesions.
MATERIALS AND METHODS
Patient series
A population-based patient series was 
prospectively collected from 2001 to 2015 and included 
718 primary tumors from patients diagnosed with 
endometrial cancer in Hordaland County (Norway). 
Clinical data were collected as previously described 
[39] and patients were surgically staged according to the 
International Federation of Gynecology and Obstetrics 
(FIGO) 2009 criteria. Samples from precursor lesions 
(complex atypical hyperplasia) were available from 
69 patients and metastasis from 142 patients (in total 
298 metastatic lesions). Fresh frozen tissue were 
investigated for gene expression for 223 patients of 
which 163 overlapped with formalin fixed paraffin 
embedded tissue (FFPE). In addition protein expression 
was investigated in 370 patients by reverse phase 
protein array (RPPA) where 306 overlapped with FFPE 
(Supplementary Table 5). 
The study has been approved by Norwegian 
legislation, including the Norwegian Data Inspectorate, 
Norwegian Social Sciences Data Services and the Western 
Regional Committee for Medical and Health Research 
Ethics (REK 2009/2315). Patients gave written informed 
consent.
Immunohistochemical staining 
Tissue microarrays (TMA) were dewaxed in 
xylene and rehydrated in graded ethanol series before 
microwave boiling in target retrieval buffer (pH9) for 
15 minutes. Staining for AR, ERα and PR expression 
was performed as previously described [6, 7, 40]. The 
staining was evaluated using a semi-quantitative system 
where both intensity and area of positive tumor cells 
is considered. Staining intensity was graded from 0 
(no staining) to 3 (strong staining), and area from 0, 1 
(< 10%), 2 (10–50%) and 3 (> 50%). A staining index 
was calculated as the product of staining intensity and 
area.  For AR and PR, staining index 0 was considered 
negative, and index 1–9 positive.  For ER index 0–3 
was defined as low, and 4–9 as high. The method for 
producing tissue microarrays (TMA) has previously been 
described and validated [41, 42]. 
Gene expression analysis
RNA was extracted from fresh frozen tissue from 
18 hyperplasias, 174 primary tumors and 42 metastases, 
and hybridized to Agilent Whole Human Genome 
Microarrays 44k (Cat. No. G4112F), according to the 
manufacturer’s instruction. The arrays were scanned and 
normalized as previously described [36]. Gene Ontology 
(GO) gene sets enriched in different groups were 
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investigated with Gene Set Enrichment Analysis (GSEA) 
using gene permutations and Significance Analysis of 
Microarray (SAM) as scoring method. The signature score 
for the cell cycle progression (CCP) signature published 
by Cuzik et al [43] was calculated as previously described 
[6]. Connectivity Map [44] was used to search for potential 
drugs based on differences in gene expression between the 
high AR to ERα ratio and the AR to ERα ratio group. 23 
cases with high ratio (≥ 1.25), and the 41 cases with lowest 
ratio (≤ 0.95) were included in the analysis. The AR to 
ER ratio based on mRNA expression was calculated by 
dividing the AR value with ER value.
Reverse phase protein array
Reverse Phase Protein Array (RPPA) was performed 
for 370 of the primary tumors as previously described 
[45, 46]. Slides were stained using antibodies as listed (https://
www.mdanderson.org/education-and-research/resources-for-
professionals/scientific-resources/core-facilities-and-services/
functional-proteomics-rppa-core/index.html). Relative protein 
levels were determined by fitting each dilution curve with a 
logistic model (‘Supercurve Fitting’ http://bioinformatics.
mdanderson.org/OOMPA) [47]. Expression levels of AR, 
ERα and proliferation cell nuclear antigen (PCNA) were 
extracted from the whole RPPA dataset. The AR to ERα ratio 
was calculated by dividing the AR value with ERα value.
Statistical analysis
Data were analyzed using SPSS version 22 (SPSS 
Inc, Chicago, IL). Probability < 0.05 was considered 
statistical significant. Associations between groups 
were evaluated using the chi-square test for categorical 
variables and the Mann-Whitney U test for continuous 
variables. Univariate survival analysis was performed 
using the Kaplan Meier (product-limit) method. Date 
of primary surgery was entry date, and date of death 
due to endometrial carcinoma was defined as event for 
estimation of disease specific survival. Survival between 
groups was compared using the log-rank (Mantel-Cox) 
test. The Cox proportional hazard regression model was 
used to evaluate the prognostic impact of AR adjusted 
for other prognostic parameters. Included in the model 
was in addition to AR; age, histologic type and grade, 
all factors with known prognostic impact in endometrial 
cancer.
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